STAT3 and breast cancer: In this study, we first reported that APX2009 impairs STAT3 transcriptional activity in breast cancer cells, leading, in combination with Stattic, to a further decrease in the survival and aggressiveness of breast cancer cells in vitro, compared to treatments alone.